Nisha Shariff, Foo Jen Chun, Susan K Parsons, David C Hodgson
{"title":"The evolution of treatment for pediatric advanced stage classic Hodgkin lymphoma - a narrative literature review.","authors":"Nisha Shariff, Foo Jen Chun, Susan K Parsons, David C Hodgson","doi":"10.1080/10428194.2025.2531154","DOIUrl":null,"url":null,"abstract":"<p><p>Recent trials introducing novel immunotherapy into the treatment of advanced-stage pediatric classic Hodgkin lymphoma (cHL) suggest that cure rates will exceed 90%. Consequently, more than ever there is a need to minimize the toxicity of treatment and ensure that survivors experience a quality of life unimpaired by late effects. We performed a structured literature review to analyze frontline trials of advanced pediatric cHL, the impact of toxicity of treatments and on health-related quality of life. A total of 6 clinical trials were included, 4 randomized phase 3 trials, 1 non-randomized phase 3 trial and 1 phase 2 trial. One longitudinal study and 5 retrospective registry-based studies were included in the health-related quality of life review. The use of novel systemic treatments has significantly improved outcomes in advanced- pediatric cHL. However, new challenges arise to better understand quality of life outcomes among survivors, and to make new drugs more widely accessible.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-13"},"PeriodicalIF":2.2000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2025.2531154","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Recent trials introducing novel immunotherapy into the treatment of advanced-stage pediatric classic Hodgkin lymphoma (cHL) suggest that cure rates will exceed 90%. Consequently, more than ever there is a need to minimize the toxicity of treatment and ensure that survivors experience a quality of life unimpaired by late effects. We performed a structured literature review to analyze frontline trials of advanced pediatric cHL, the impact of toxicity of treatments and on health-related quality of life. A total of 6 clinical trials were included, 4 randomized phase 3 trials, 1 non-randomized phase 3 trial and 1 phase 2 trial. One longitudinal study and 5 retrospective registry-based studies were included in the health-related quality of life review. The use of novel systemic treatments has significantly improved outcomes in advanced- pediatric cHL. However, new challenges arise to better understand quality of life outcomes among survivors, and to make new drugs more widely accessible.
期刊介绍：
Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
